Aptivus Adds Warning On Intracranial Hemorrhaging To Black Box
This article was originally published in The Pink Sheet Daily
Executive Summary
Labeling for Boehringer Ingelheim’s HIV drug was updated based on Phase III data of tipranavir coadministered with ritonavir (Abbott’s Norvir).
You may also be interested in...
Boehringer Ingelheim’s HIV Therapy Aptivus Gets Full FDA Approval
Protease inhibitor received accelerated approval in June 2005, but FDA requested additional post-marketing trials.
Boehringer Ingelheim’s HIV Therapy Aptivus Gets Full FDA Approval
Protease inhibitor received accelerated approval in June 2005, but FDA requested additional post-marketing trials.
Aptivus Labeling Recommends Genotypic And Liver Function Testing
Labeling for Boehringer Ingelheim's HIV therapy recommends genotypic or phenotypic testing and liver function testing prior to therapy. Aptivus (tipranavir) clears FDA with a "black box" warning on hepatitis and hepatic decompensation and extensive drug-drug interactions.